Affiliations: [a] Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia | [b] Axon Neuroscience SE, Bratislava, Slovakia
Correspondence:
[*]
Correspondence to: Prof. Michal Novak, MDV, PhD, DSc, Dr.h.c., Institute of Neuroimmunology, Slovak Academy of Sciences, Dubravska street 9, 84510 Bratislava, Slovak Republic. Fax: +421 2 5477 4276; E-mail: [email protected].
Note: [1] These authors contributed equally.
Abstract: Misfolded, N- and C-terminally truncated tau protein is the primary constituent of neurofibrillary tangles in brains of patients afflicted with Alzheimer's disease (AD). Intracellular accumulation of misfolded and truncated tau leads to generation of cytotoxic intermediates; transgenic expression of truncated tau leads to neurological deficits, neurofibrillary degeneration, and premature death of animals. Since no cure for AD or other tauopathies is available yet, we tested the possibility for prevention of pathogenic events elicited by tau, via inhibition of its intracellular accumulation. Using a cell model conditionally expressing truncated and misfolding-prone tau protein, we showed that pathogenic forms of tau are degraded via the proteasome. We have also observed that chymotrypsin-like activity of the proteasome was significantly suppressed (a decrease of ∼29.12% in comparison to control cells; p < 0.001) as a consequence of truncated tau expression. Interestingly, the activity of the proteasome was enhanced by geldanamycin, a natural inhibitor of Hsp90. This activation resulted in accelerated degradation of misfolded tau. We suggest that non-toxic inhibitors of Hsp90, especially those which can activate the proteasome, are good candidates for the development of molecules that efficiently counteract the damaging effects of pathologically misfolded proteins.
Keywords: Cellular model, geldanamycin, proteasome, protein tau
